BusinessNews brief
For Novartis, M&A is both a disease and cure
The Swiss firm's market value fell over $30 bln after a drug acquired in a recent takeover disappointed, prompting calls for a board shake-up. But expiring patents in coming years will force CEO Vas Narasimhan to do deals. That may be harder if he is distracted by investor anger.
Sources and context
ReutersSource headline and summary supplied via NewsData.io. First collected by NewsJaws on 2026-09-12. This is an automated news brief, not original NewsJaws reporting. Dates reflect the source publication. Feed delays may apply.